ASRM 2019 Scientific Congress Prize Paper Session 1
The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the Prize Paper Candidates’ session on Tuesday.
FOR US AUDIENCES ONLY
ExEm® Foam is an innovative, FDA-approved product that offers a less invasive and effective alternative to other tubal patency assessment procedures, like laparoscopy or X-Ray HSG.
ExEm® Foam Inc. is an affiliate of IQ MEDICAL VENTURES, B.V. ExEm® is a registered trademark of GISKIT PHARMA B.V.
Important Safety Information: ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting. Click here for full prescribing information.
References:
1. Ludwin I., Ludwin, A. et al. Accuracy of hysterosalpingo-foam sonography in comparison to hysterosalpingo-contrast sonography with air/saline and to laparoscopy with dye. Human Reproduction 2017, 32(4):758–69
2. Riganelli L., Casorelli A. et al. Ultrasonography reappraisal of tubal patency in assisted reproduction technology patients: comparison between 2D and3D-sonohysterosalpingography. A pilot study. Minerva Ginecologica 2018, 70(2):123-28
3. Dreyer, K., Out, R. et al. Hysterosalpingo-foam sonography, a less painful procedure for tubal patency testing during fertility workup compared with (serial) hysterosalpingography: A randomized controlled trial. Fertility and Sterility 2014, 102(3):821-25
ExEm_US_02_v27
ExEm® Foam Inc. is an affiliate of IQ MEDICAL VENTURES, B.V. ExEm® is a registered trademark of GISKIT PHARMA B.V.